Showing 1341-1350 of 3001 results for "".
- Tolebrutinib Treatment Lowered Disease Activity of Relapsing Multiple Sclerosishttps://practicalneurology.com/news/tolebrutinib-treatment-lowered-disease-activity-of-relapsing-multiple-sclerosis/2469721/In a phase 2b study, participants with relapsing multiple sclerosis (RMS) treated with tolebrutinib (SAR442168; Sanofi, Bridgewater, NJ) had reduced MS disease activity measured by MRI. Participants received 5, 15, 30, or 60 mg/day tolebrutinib for 14 weeks and then 60 mg/day for the following 34
- Game-Based Digital Therapy for Individuals With Multiple Sclerosis Reduces Anxietyhttps://practicalneurology.com/news/game-based-digital-therapy-for-individuals-with-multiple-sclerosis-reduces-anxiety/2469670/Use of a game-based digital therapy (Personal Zen; Wise Therapeutics, New York, NY) reduced symptoms of anxiety in individuals with multiple sclerosis (MS). The digital therapy requires a prescription and uses adaptive, personalized gameplay to address mental health needs, and can serve as an at-
- Natalizumab Every 6 Weeks Is Effective for Treatment of Multiple Sclerosis and Reduces Riskhttps://practicalneurology.com/news/natalizumab-every-6-weeks-is-effective-for-treatment-of-multiple-sclerosis-and-reduces-risk/2469657/Treatment of multiple sclerosis (MS) with 300 mg natalizumab (Tysabri; Biogen, Cambridge, MA) every 6 weeks vs every 4 weeks was evaluated in the phase 3b NOVA study (NCT03689972). Both dosing intervals were found equally effective in
- Immune Repopulation Study Suggests Cladribine Has No Negative Effect on Ability to Fight Injection or Benefit From Vaccinationhttps://practicalneurology.com/news/immune-repopulation-study-suggests-cladribine-has-no-negative-effect-on-ability-to-fight-injection-or-benefit-from-vaccination/2469580/New research suggests that cladribine (Mavenclad; Merck KGaA, Darmstadt, Germany) treatment for relapsing multiple sclerosis (RMS) does not diminish individuals' ability to fight infection or form antibodies after immunization. The MAGNIFY-MS sub-study (
- Vidofludimus Calcium a Selective T- and B-Cell Reduced Multiple Sclerosis Disease Activityhttps://practicalneurology.com/news/vidofludimus-calcium-a-selective-t-and-b-cell-reduced-multiple-sclerosis-disease-activity/2469566/In the phase 2 EMPhASIS trial (NCT03846219) vidofludimus calcium (VFC)(IMU-838; Immunic, New York, NY) reduced new combined unique active (CUA) MRI lesions in individuals with multiple sclerosis (MS). CUA is a measure that counts uniqu
- Black People May Respond Differently to Anti-CD20 Treatment for Multiple Sclerosishttps://practicalneurology.com/news/black-people-may-respond-differently-to-anti-cd20-treatment-for-multiple-sclerosis/2469561/A preliminary retrospective study suggests Black people may respond differently to antiCD20 treatments commonly used to treat multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). After treatment with B-cell depleting antiCD20 agents rituximab or ocrelizumab via infusion, Bla
- FDA Gives Marketing Authorization to Translingual Neuromodulation Device for Treatment of Gait Deficits in Multiple Sclerosishttps://practicalneurology.com/news/fda-gives-marketing-authorization-to-translingual-neuromodulation-device-for-treatment-of-gait-deficits-in-multiple-sclerosis/2469546/The Food and Drug Administration (FDA) authorized marketing of a tongue-delivered portable neuromodulation device (PoNS; Helius Medical, Newtown, PA) to treat gait deficit caused by multiple sclerosis (MS). The device is a prescription only adjunct to a supervised therapeutic exercise program for
- FDA Approves Ponesimod for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/fda-approves-ponesimod-for-relapsing-multiple-sclerosis/2469532/The Food and Drug Administration (FDA) has approved ponesimod (Ponvory; Janssen, Titusville, NJ) for the treatment of relapsing forms of multiple sclerosis (MS). Ponesimode is an oral medication, taken once daily. In a randomized double-blind head-to-head phase 3 clinical trial (
- Multiple Sclerosis Symptoms May Worsen With Higher Than Average Temperatureshttps://practicalneurology.com/news/multiple-sclerosis-symptoms-may-worsen-with-higher-than-average-temperatures/2469518/A preliminary study reveals that in months when the average environmental temperature was higher than the long-term average by 2 degrees Fahrenheit, people with multiple sclerosis (MS) had an increased rate of hospital service use. During periods of anomalously wa
- Continued Use of Disease-Modifying Therapy During Pregnancy May Reduce Hospitalizationhttps://practicalneurology.com/news/continued-use-of-disease-modifying-therapy-during-pregnancy-may-reduce-hospitalization/2469515/Results of a study from AllianceRx Walgreens Prime showed individuals with multiple sclerosis (MS) who are pregnant typically reduce use of disease-modifying therapies (DMTs). A significant number, however, continue treatment with high adherence levels (proportion of days covered [PDC] ≥.80).